abstract |
The present invention relates to the field of tumor immunotherapy, and relates to a humanized anti-VEGF Fab antibody fragment. Disclosed in the present invention are a nucleic acid sequence encoding the antibody fragment (comprising heavy/light chain variable regions), a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The anti-VEGF Fab antibody fragment disclosed in the present invention can be specifically bound to VEGF with high affinity, can block VEGF from binding to a receptor VEGFR2, and can also neutralize the proliferation effect of VEGF on HUVEC cells. Compared with the full-length structure, the antibody of the Fab fragment has stronger penetrability, and lower toxic and side effects such as gastrointestinal perforation, hypertension, and hemorrhage and cannot excite the complement cascade reaction, thereby reducing the risk of initiating intraocular inflammation and autoimmune inflammatory response. The antibody can be used to clinically treat various ocular diseases characterized by choroidal neovascularization, comprising but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, and choroidal neovascularization (CNV). |